Home Supplements That Start With P Polysaccharide-K clinical evidence, cancer outcomes, dosage guidelines, and side effects

Polysaccharide-K clinical evidence, cancer outcomes, dosage guidelines, and side effects

By
Vita Library
-
219

Polysaccharide-K, often shortened to PSK and sometimes called Krestin, is a protein-bound polysaccharide extracted from the medicinal mushroom Trametes versicolor (turkey tail). It has been used for decades in Japan as a licensed adjuvant treatment alongside chemotherapy, especially for stomach and colorectal cancers. Outside Asia it is usually sold as a dietary supplement in mushroom formulas aimed at immune and wellness support.

Interest in PSK comes from two main areas. First, it appears to act as an immunomodulator, helping immune cells communicate and respond more effectively rather than simply “boosting” them. Second, several clinical trials, mainly from Japan, suggest that adding PSK to standard cancer treatment may modestly improve survival and reduce relapse in some gastrointestinal cancers. At the same time, research is still evolving, products vary in quality, and it is not a magic bullet.

This guide explains what PSK is, how it seems to work, where evidence is strongest, how it is typically used and dosed, and what to know about safety and side effects.

Key Insights

  • Polysaccharide-K is a protein-bound beta glucan from turkey tail mushroom used mainly as an immune modulator and oncology adjuvant.
  • Clinical trials suggest added PSK may modestly improve survival when combined with chemotherapy in some gastrointestinal cancers, but it is not a standalone cure.
  • Typical studied doses are around 3 g per day orally, usually divided into two or three doses with food.
  • Common side effects include mild digestive upset and fatigue; serious reactions are rare but possible.
  • People on immunosuppressive drugs, with autoimmune disease, organ transplants, or who are pregnant should avoid PSK unless specifically supervised by a specialist.

Table of Contents

What is Polysaccharide-K and how it works

Polysaccharide-K is a protein-bound polysaccharide isolated from the cultured mycelium (the root-like growth stage) of Trametes versicolor, a bracket fungus better known as turkey tail mushroom. Chemically, PSK is mostly beta glucans linked to peptide fragments. These beta glucans are long chains of glucose with a specific branching pattern that immune cells recognise as “danger” signals associated with fungi.

In Japan, PSK has been approved as a prescription drug since the 1970s and is used as an adjuvant (add-on) to chemotherapy and, in some cases, radiotherapy for certain cancers. It is usually manufactured under pharmaceutical standards from a defined mushroom strain, which gives more consistency than many over-the-counter extracts.

The key interest in PSK is its immunomodulating activity. Rather than acting as a direct cytotoxic chemotherapy, PSK seems to:

  • Bind to pattern recognition receptors on immune cells, especially Toll-like receptors (such as TLR2) and receptors for beta glucans on macrophages, dendritic cells, and neutrophils.
  • Increase activity of natural killer (NK) cells, cytotoxic T lymphocytes, and other effector cells that help detect and attack tumour cells or virus-infected cells.
  • Shift cytokine signalling, encouraging a more balanced and coordinated immune response; for example, raising levels of interleukin-2 and interferon gamma while supporting antigen presentation.
  • Influence the tumour microenvironment by reducing some immunosuppressive signals and improving infiltration of immune cells into tumour tissue, at least in animal models.
  • Provide some antioxidant and anti-inflammatory effects, which may help protect normal tissues during chemotherapy.

Because PSK acts on immune balance rather than simply stimulating it, researchers sometimes describe it as an “immunomodulator” or “biological response modifier.” In practice, that means its effects can depend on the existing immune state, other medications, and the underlying disease.

Back to top ↑

Evidence based benefits of Polysaccharide-K

Most of what we know about PSK comes from clinical studies in Japan and parts of East Asia, where it has been integrated into oncology practice for several decades. Much of the research focuses on patients with solid tumours receiving surgery and chemotherapy, with PSK added as long term adjuvant therapy.

Areas where evidence is relatively stronger include:

  • Gastric (stomach) cancer
    Several randomised trials have evaluated PSK added to standard chemotherapy after surgery for resected gastric cancer. In a number of these studies, patients taking PSK plus chemotherapy showed improved disease free and overall survival compared with chemotherapy alone, particularly in certain stages of disease. The benefit is not universal across all trials, but meta analyses generally suggest a modest survival advantage.
  • Colorectal cancer
    Similar adjuvant trials in colorectal cancer have reported better recurrence free survival and, in some studies, higher overall survival when PSK is included after curative surgery and chemotherapy. The magnitude of benefit is typically modest, but clinically meaningful in some subgroups, such as stage II or III disease.
  • Lung and other solid tumours
    There are also trials and observational studies suggesting improved survival or response rates in lung cancer and some other solid tumours when PSK is used alongside conventional treatment. However, these data are more variable, and trial designs differ widely.

Beyond survival, PSK may offer additional benefits:

  • Immune function
    Clinical studies in cancer patients have reported improvements in immune markers such as NK cell activity, T cell counts, and cytokine profiles during chemotherapy when PSK is added. These immunologic changes may help explain the survival benefits seen in some trials.
  • Quality of life and treatment tolerance
    Some studies report better appetite, performance status, or less fatigue in patients taking PSK with chemotherapy. There is also evidence that PSK may reduce chemotherapy related suppression of certain immune cell populations, potentially helping patients complete planned treatment courses.

Outside oncology, research on PSK for infections, chronic fatigue, or general immune support is limited and less rigorous. While laboratory work shows antiviral and antibacterial effects, these findings have not yet translated into strong clinical evidence in non cancer populations.

Overall, PSK appears most promising as a carefully selected adjuvant in specific cancer settings rather than as a general immune supplement for healthy individuals.

Back to top ↑

Therapeutic uses and how PSK is taken

In practice, PSK is used in two very different ways depending on the country:

  1. As a prescription adjuvant in oncology (mainly Japan and some Asian countries)
  • PSK (Krestin) is prescribed to patients with gastric, colorectal, and sometimes other cancers, usually after surgery and in combination with chemotherapy.
  • It is typically taken orally as granules or capsules, often for months to years as a maintenance therapy.
  • The goal is not to replace chemotherapy but to support the immune system, improve treatment tolerance, and reduce the risk of relapse.
  1. As a dietary supplement in the rest of the world
  • Outside Asia, PSK is not usually licensed as a drug. Instead, turkey tail mushroom extracts, sometimes standardised to PSK or the related compound PSP, are sold as supplements.
  • These products may vary widely in mushroom species, extraction method, beta glucan content, and presence of protein bound polysaccharides. Many are blends rather than pure PSK.

Common reasons people consider PSK or turkey tail extracts include:

  • As part of an integrative oncology plan, usually alongside standard treatment and under the guidance of an oncologist or integrative medicine specialist.
  • For perceived immune support during or after cancer therapy.
  • Occasionally for chronic viral infections or immune imbalance, though robust clinical evidence is sparse.

Typical administration patterns:

  • Form: Granules, capsules, tablets, or powders. True PSK drugs in Japan are standardised pharmaceutical products, while supplements can be hot water or alcohol extracts, whole mushroom powders, or protein-bound fractions.
  • Timing: Usually taken orally two or three times daily. Taking PSK with food can reduce stomach upset, although some protocols specify taking it between meals.
  • Duration: In oncology trials, PSK is often continued for one to three years after surgery and chemotherapy. In supplement use, durations are more variable, often ranging from several weeks to many months.

Because the quality of non prescription products can vary, people considering PSK as part of cancer care should ideally:

  • Discuss plans with their oncology team.
  • Choose products that disclose mushroom species, extraction method, and measured beta glucan or PSK content.
  • Avoid replacing or delaying proven conventional treatments in favour of PSK alone.

Back to top ↑

Polysaccharide-K dosage and practical guidelines

There is no single universal dosage for PSK, but clinical oncology protocols in Japan provide a practical reference point.

Typical studied doses

  • In many gastric and colorectal cancer trials, PSK was given at about 3 g per day, taken orally in three divided doses of 1 g each, usually with meals.
  • Some protocols used slightly lower or higher amounts (for example, 1 to 3 g per day) depending on body weight, treatment phase, and combination with chemotherapy.

When PSK is used as a dietary supplement rather than a prescription drug, labels may suggest a broad range such as 1–3 g of extract per day. It is important to distinguish between:

  • Pure PSK or PSK enriched extracts (closer to the Japanese drug product), and
  • General turkey tail powders or blends that may have lower concentrations of the active protein-bound polysaccharides.

General practical considerations

If an oncologist or integrative physician decides PSK is appropriate as part of a treatment plan, they will individualise the dose. Common principles include:

  • Start at a lower dose and build up over one to two weeks to gauge tolerance, especially in patients who are frail or experiencing significant chemotherapy side effects.
  • Use divided doses (for example, 2–3 times daily) to maintain more stable exposure and reduce digestive upset.
  • Align duration with treatment goals, such as continuing PSK through chemotherapy and for a defined maintenance period afterward.

For people without cancer who are considering PSK for general immune support, there is no strong evidence base to define an ideal dose. Many practitioners, when they use it at all, stay in the lower range (for example, 500–1000 mg per day of a high quality extract) and limit duration to a few months, with breaks.

Special populations

  • Children and adolescents: Safety and optimal dosing are not well established. Paediatric use should only be considered under specialist supervision within a structured clinical plan.
  • Older adults: Often well tolerated, but dose adjustments may be needed due to comorbidities and polypharmacy.
  • Pregnancy and breastfeeding: Because robust safety data are lacking, most experts advise avoiding PSK in pregnancy and while nursing.

Whatever the context, PSK should never be started, stopped, or dose adjusted without informing the treating medical team, particularly when chemotherapy, immunotherapy, or other critical drugs are involved.

Back to top ↑

Side effects, interactions, and who should avoid PSK

In clinical trials and post marketing experience, PSK is generally described as well tolerated, especially compared with many oncology drugs. However, “well tolerated” does not mean side effect free, and certain groups should approach PSK with great caution or avoid it altogether.

Commonly reported side effects

These are usually mild to moderate and often improve over time or with dose adjustment:

  • Digestive symptoms: nausea, soft stools or mild diarrhoea, constipation, abdominal discomfort, bloating, or decreased appetite.
  • Fatigue or a sense of heaviness.
  • Changes in taste or mild headache in some patients.
  • Skin changes such as darkening of nails or skin in a minority of users.

Because many PSK studies took place in people also receiving chemotherapy, it can be hard to separate side effects caused by PSK from those due to other drugs. Still, overall rates of serious toxicity attributable solely to PSK appear low in published reports.

Less common but more serious concerns

  • Allergic or hypersensitivity reactions: As a mushroom derived product, PSK can theoretically provoke allergic reactions, especially in people with known mushroom allergies. Symptoms could include rash, itching, swelling, or difficulty breathing and would require immediate medical attention.
  • Immune imbalance: In theory, altering immune signalling could worsen certain autoimmune diseases, although there is limited direct evidence. Caution is advisable.

Potential interactions

Because PSK acts on the immune system and may influence drug metabolism and distribution, it can interact with other therapies:

  • Chemotherapy and targeted therapies: PSK is often intentionally combined with chemotherapy in Japanese protocols, but this is carefully controlled. When used outside those settings, PSK could alter immune responses or side effect profiles in unpredictable ways. Any use with chemotherapy, immunotherapy, or targeted drugs should be guided by an oncologist familiar with the evidence.
  • Immunosuppressants: For people on drugs such as tacrolimus, cyclosporine, high dose corticosteroids, or biologic agents for autoimmune disease, PSK’s immunomodulating effects may counteract or unpredictably alter drug actions.
  • Anticoagulants and antiplatelet agents: Some medicinal mushrooms have mild effects on platelet function or blood flow. While strong data are limited for PSK, caution is wise if someone is taking warfarin, direct oral anticoagulants, or antiplatelet drugs.

Who should avoid or use PSK only under strict supervision

  • People with organ transplants or those on strong immunosuppressive regimens.
  • Individuals with active autoimmune disease unless fully evaluated and supervised by a specialist team.
  • Pregnant or breastfeeding women, due to insufficient safety data.
  • People with a history of severe mushroom allergy.
  • Anyone considering PSK as a substitute for standard cancer treatment; relying on PSK instead of proven therapies is not safe.

Even when PSK seems appropriate, close communication between the person, their oncologist, and any integrative practitioner is essential to monitor for interactions, side effects, and effectiveness.

Back to top ↑

Research summary and how to think about PSK

Polysaccharide-K occupies an unusual position between conventional and complementary medicine. It is one of the more extensively studied mushroom derived compounds, with dozens of clinical trials and several systematic reviews, yet most of this work has been done in specific populations under a particular health system.

Key points from the research landscape include:

  • Evidence base
    Multiple studies, along with more recent systematic reviews, suggest that PSK can modestly improve survival and reduce recurrence when used as an adjuvant with chemotherapy in certain cancers, especially gastric and colorectal. These benefits do not apply evenly to every cancer type or stage, and not every trial shows a strong effect, but the overall pattern is more encouraging than for many other natural products.
  • Mechanistic plausibility
    Laboratory and translational studies show that PSK interacts with innate and adaptive immunity, alters cytokine profiles, and appears to modulate the tumour microenvironment. These mechanisms are consistent with improved host defence against residual tumour cells and better resilience during chemotherapy.
  • Gaps and limitations
    Many PSK trials are older, and cancer treatment standards have changed significantly (for example, modern targeted therapies and immunotherapies). There are relatively few high quality studies in Western populations, and the licensed drug form is not widely available outside Asia. Supplement products may not be equivalent to the PSK used in clinical trials.
  • Regulatory and guideline perspectives
    In Japan and some neighbouring countries, PSK is integrated into standard oncology protocols. In North America and Europe, regulatory agencies view PSK containing products as dietary supplements rather than drugs, and oncology guidelines generally see mushroom extracts as investigational. Some integrative oncology centres may consider PSK for individual patients, but this is not yet a mainstream recommendation.

How should a patient or clinician think about PSK today?

  • PSK is best viewed as a potential adjunct in a broader, evidence informed treatment plan, not as a replacement for surgery, chemotherapy, radiotherapy, or targeted therapies when those are indicated.
  • Its use is most reasonable when:
  • There is a clear, well studied indication (for example, certain resected gastrointestinal cancers).
  • A standardised, reliable PSK product is available.
  • An experienced oncology team is on board, and monitoring is in place.
  • For general wellness or non cancer uses, PSK should be approached more cautiously since robust benefit data are limited, and simpler strategies (nutrition, exercise, sleep, stress management, vaccination) have stronger evidence.

If you are considering PSK, the most important steps are to talk openly with your oncologist or primary care clinician, avoid self prescribing high doses, and ensure that any supplement use does not delay or replace proven medical care.

Back to top ↑

References

Disclaimer

The information in this article is for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Polysaccharide-K is a biologically active substance that can interact with medications and medical conditions. Always consult your physician, oncologist, or another qualified health professional before starting, changing, or stopping any supplement or therapy, especially in the context of cancer or chronic illness. Never delay or disregard professional medical advice because of something you have read online.

If you found this guide useful, you are welcome to share it with others on Facebook, X (formerly Twitter), or any platform you prefer, and to follow our work on social media. Your considerate sharing helps support our team in continuing to create careful, evidence informed health content.

RELATED ARTICLESMORE FROM AUTHOR